These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 9887233)

  • 1. Perceptions of cisplatin-related toxicity among ovarian cancer patients and gynecologic oncologists.
    Calhoun EA; Bennett CL; Peeples PA; Lurain JR; Roland PY; Weinstein JM; Fishman DA
    Gynecol Oncol; 1998 Dec; 71(3):369-75. PubMed ID: 9887233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of ovarian cancer treatments: analysis of utility assessments of ovarian cancer patients, at-risk population, general population, and physicians.
    Calhoun EA; Fishman DA; Lurain JR; Welshman EE; Bennett CL
    Gynecol Oncol; 2004 Apr; 93(1):164-9. PubMed ID: 15047231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of the gynecologic oncologist on the survival of ovarian cancer patients.
    Chan JK; Kapp DS; Shin JY; Husain A; Teng NN; Berek JS; Osann K; Leiserowitz GS; Cress RD; O'Malley C
    Obstet Gynecol; 2007 Jun; 109(6):1342-50. PubMed ID: 17540806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
    Greimel ER; Bjelic-Radisic V; Pfisterer J; Hilpert F; Daghofer F; du Bois A;
    J Clin Oncol; 2006 Feb; 24(4):579-86. PubMed ID: 16446330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study.
    Wenzel LB; Huang HQ; Armstrong DK; Walker JL; Cella D;
    J Clin Oncol; 2007 Feb; 25(4):437-43. PubMed ID: 17264340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A population-based study of patterns of care for ovarian cancer: who is seen by a gynecologic oncologist and who is not?
    Carney ME; Lancaster JM; Ford C; Tsodikov A; Wiggins CL
    Gynecol Oncol; 2002 Jan; 84(1):36-42. PubMed ID: 11748973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncologist preferences for health states associated with the treatment of advanced ovarian cancer.
    Hess LM; Malone DC; Skrepnek GH; Reed PG; Armstrong E; Coons SJ
    Appl Health Econ Health Policy; 2010; 8(4):217-23. PubMed ID: 20578777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paclitaxel, carboplatin, and hexamethyl-melamine (taxchex) as first-line therapy for ovarian cancer.
    Hartenbach EM; Harris LS; Bailey HH; Grosen EA; Larrison E; Chen D; Twiggs LB; Schink JC
    Cancer J Sci Am; 1999; 5(6):348-55. PubMed ID: 10606476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
    Covens A; Blessing J; Bender D; Mannel R; Morgan M;
    Gynecol Oncol; 2006 Mar; 100(3):586-90. PubMed ID: 16249022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study.
    Bezjak A; Tu D; Bacon M; Osoba D; Zee B; Stuart G; Roy JA; Piccart M; Eisenhauer E
    J Clin Oncol; 2004 Nov; 22(22):4595-603. PubMed ID: 15466785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study.
    Monk BJ; Huang HQ; Cella D; Long HJ;
    J Clin Oncol; 2005 Jul; 23(21):4617-25. PubMed ID: 15911864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin as initial chemotherapy in ovarian carcinosarcomas: a Gynecologic Oncology Group study.
    Tate Thigpen J; Blessing JA; DeGeest K; Look KY; Homesley HD;
    Gynecol Oncol; 2004 May; 93(2):336-9. PubMed ID: 15099942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Which dimensions of health-related quality of life are altered in patients attending the different gynecologic oncology health care settings?
    Capelli G; De Vincenzo RI; Addamo A; Bartolozzi F; Braggio N; Scambia G
    Cancer; 2002 Dec; 95(12):2500-7. PubMed ID: 12467063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of life evaluations in patients with ovarian cancer during chemotherapy treatment.
    Le T; Leis A; Pahwa P; Wright K; Ali K; Reeder B; Hopkins L; Fung MF
    Gynecol Oncol; 2004 Mar; 92(3):839-44. PubMed ID: 14984950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does ovarian cancer treatment and survival differ by the specialty providing chemotherapy?
    Silber JH; Rosenbaum PR; Polsky D; Ross RN; Even-Shoshan O; Schwartz JS; Armstrong KA; Randall TC
    J Clin Oncol; 2007 Apr; 25(10):1169-75. PubMed ID: 17401005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of life in ovarian cancer patients receiving chemotherapy.
    Lakusta CM; Atkinson MJ; Robinson JW; Nation J; Taenzer PA; Campo MG
    Gynecol Oncol; 2001 Jun; 81(3):490-5. PubMed ID: 11371144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent weekly cisplatin and radiotherapy in routine management of cervical cancer: a report on patient compliance and acute toxicity.
    Serkies K; Jassem J
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):814-21. PubMed ID: 15465198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma: a Gynecologic Oncology Group study.
    Feun LG; Blessing JA; Major FJ; DiSaia PJ; Alvarez RD; Berek JS
    Gynecol Oncol; 1998 Dec; 71(3):410-5. PubMed ID: 9887240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot.
    van der Vange N; van Goethem AR; Zoetmulder FA; Kaag MM; van de Vaart PJ; ten Bokkel Huinink WW; Beijnen JH
    Eur J Surg Oncol; 2000 Nov; 26(7):663-8. PubMed ID: 11078613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer.
    Berry E; Matthews KS; Singh DK; Buttin BM; Lurain JR; Alvarez RD; Schink J
    Gynecol Oncol; 2009 Apr; 113(1):63-7. PubMed ID: 19201457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.